Valuation: Prothena Corporation plc

Market Cap 440M 383M 356M 327M 618M 42.03B 627M 4.2B 1.65B 20.92B 1.65B 1.62B 70.16B P/E 2026 *
-117x
P/E 2027 * -8.55x
Enterprise Value 440M 383M 356M 327M 618M 42.03B 627M 4.2B 1.65B 20.92B 1.65B 1.62B 70.16B EV / Sales 2026 *
5.28x
EV / Sales 2027 * 20x
Free-Float
79.82%
Yield 2026 *
-
Yield 2027 * -
1 day-3.75%
1 week-7.03%
Current month-16.91%
1 month-15.08%
3 months-23.54%
6 months-8.70%
Current year-14.82%
1 week 8
Extreme 8
9.13
1 month 8
Extreme 8
10.15
Current year 7.73
Extreme 7.73
11.8
1 year 6.61
Extreme 6.61
11.8
3 years 4.32
Extreme 4.32
70.09
5 years 4.32
Extreme 4.32
79.75
10 years 4.32
Extreme 4.32
79.75
Manager TitleAgeSince
Chief Executive Officer 57 29/09/2016
Director of Finance/CFO 52 31/03/2013
Chief Operating Officer 52 28/09/2021
Director TitleAgeSince
Chairman 76 19/12/2012
Director/Board Member 72 19/12/2012
Director/Board Member 63 19/12/2012
Date Insider Type Main position Quantity % Market Cap.
04/06/26 Buy 50,000 0.0955%
02/06/26 Buy 50,000 0.0955%
28/07/25 Free

Chief Technology Officer

85,000 0.1580%
Change 5-day change 1-year change 3-year change Capi.($)
-3.51%-7.03%+18.41%-88.19% 440M
+2.35%+0.77%+29.92%+85.38% 55.23B
-0.21%-6.52%+42.39%+64.10% 53.75B
-2.36%+1.53%-15.63%-16.69% 23.48B
-3.10%-7.90%-8.21%+345.77% 22B
+2.49%-1.27%+15.99%-10.53% 19.78B
+0.79%-1.06%+29.29%-33.32% 17.44B
+0.58%-7.23%+24.50%+519.07% 14.66B
-5.43%-3.76%+47.13%+170.37% 14.07B
+3.41%-7.83%+161.76%+284.91% 13.02B
Average -0.54%-1.15%+34.55%+132.09% 23.39B
Weighted average by Cap. +0.13%+0.10%+31.41%+120.85%

Financials

2026 *2027 *
Net sales 83.32M 72.43M 67.42M 61.9M 117M 7.95B 119M 795M 312M 3.96B 313M 306M 13.28B 22M 19.12M 17.8M 16.34M 30.86M 2.1B 31.34M 210M 82.35M 1.05B 82.62M 80.81M 3.51B
Net income 2.42M 2.11M 1.96M 1.8M 3.4M 231M 3.45M 23.11M 9.07M 115M 9.1M 8.9M 386M -55.93M -48.62M -45.25M -41.55M -78.46M -5.34B -79.67M -533M -209M -2.66B -210M -205M -8.91B
Net Debt - -
Logo Prothena Corporation plc
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
Employees
67
Date Price Change Volume
31/07/26 US$8.135 -3.27% 344,079
30/07/26 US$8.410 -1.75% 502,233
29/07/26 US$8.560 0.00% 641,215
28/07/26 US$8.560 -1.61% 802,255
27/07/26 US$8.700 -0.57% 704,707
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
8.410USD
Average target price
21.40USD
Spread / Average Target
+154.46%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PRTA Stock